Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

ADIAL PHARMACEUTICALS, INC.

ADIL · Nasdaq · CIK 0001513525 · Healthcare · Biotechnology

INSIDER SIGNAL

40.9 / 100

1 buyers · 5 purchase transaction lines · $106.3K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+7.8 / 25
Role+14.0 / 20
Recency+2.1 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: TenPercentOwner (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Coastlands Capital LPTenPercentOwner
●●●●●
Davidson MattChief Development Officer
○○○
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Coastlands Capital LP · $106.3K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-06-29–2026-07-14

Roles in the peak window: TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

40.9 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 41.2
  2. 41.1
  3. 41.0
  4. 41.0
  5. 40.9

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

5Purchases
0Sales
10Other Form 4 lines
9SEC filings · 365 days
BUYING5 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER5 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-34.7%
3M
+49.5%
6M
+148.6%
12M
-56.5%

Volatility & liquidity

Volatility
118.6%
Beta
1.50
Avg daily value
USD 247,806

Valuation

Market cap
USD 11.4M
P/E
—

Fundamentals

Profit margin
0.0%
ROE
-151184385.1%
Industry
Biotechnology

Market data

Price data up to: 2026-10-05 · Price source: OpenBB/yfinance · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · From Yahoo Finance: Market cap, Profit margin · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
183,323
Previous report
209,983
Avg daily volume
42,787
Days to cover
4.3

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-16Coastlands Capital LPPurchase (P)Common Stock1,233USD 2.75USD 3,391SEC filing ↗
2026-07-14Coastlands Capital LPPurchase (P)Common Stock2,000USD 2.65USD 5,300SEC filing ↗
2026-07-10Coastlands Capital LPPurchase (P)Common Stock1,700USD 2.70USD 4,590SEC filing ↗
2026-07-09Coastlands Capital LPPurchase (P)Common Stock10,053USD 2.79USD 28,048SEC filing ↗
2026-06-29Coastlands Capital LPPurchase (P)Common Stock25,000USD 2.60USD 65,000SEC filing ↗
2023-09-29Schuyler KevinPurchase (P)Common Stock700USD 2.74USD 1,918SEC filing ↗
2021-12-30Newman James W. Jr.Purchase (P)Common Stock25,000USD 2.69USD 67,300SEC filing ↗
2021-11-30Stilley William B. IIIPurchase (P)Common Stock10,600USD 2.75USD 29,150SEC filing ↗
2021-11-29Stilley William B. IIIPurchase (P)Common Stock10,000USD 2.59USD 25,900SEC filing ↗
2021-11-26Newman James W. Jr.Purchase (P)Common Stock10,000USD 2.85USD 28,500SEC filing ↗
2020-03-27Newman James W. Jr.Purchase (P)Common Stock19,644USD 1.36USD 26,769SEC filing ↗
2020-03-26Stilley William B. IIIPurchase (P)Common Stock12,652USD 1.47USD 18,598SEC filing ↗
2020-03-25Stilley William B. IIIPurchase (P)Common Stock12,348USD 1.13USD 13,953SEC filing ↗

Form 4 evidence

15 transaction lines in the latest 365-day window; 44 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-16Coastlands Capital LPPurchase (P)Common Stock1,233USD 2.75USD 3,391SEC filing ↗
2026-07-14Coastlands Capital LPPurchase (P)Common Stock2,000USD 2.65USD 5,300SEC filing ↗
2026-07-10Coastlands Capital LPPurchase (P)Common Stock1,700USD 2.70USD 4,590SEC filing ↗
Show recent Form 4 evidence (13 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-07-16Coastlands Capital LPPurchase (P)Common Stock1,233USD 2.75USD 3,391SEC filing ↗
2026-07-14Coastlands Capital LPPurchase (P)Common Stock2,000USD 2.65USD 5,300SEC filing ↗
2026-07-10Coastlands Capital LPPurchase (P)Common Stock1,700USD 2.70USD 4,590SEC filing ↗
2026-07-09Coastlands Capital LPPurchase (P)Common Stock10,053USD 2.79USD 28,048SEC filing ↗
2026-06-29Coastlands Capital LPPurchase (P)Common Stock25,000USD 2.60USD 65,000SEC filing ↗
2026-06-12Davidson MattAward / grant (A)Common Stock232,417USD 0.00USD 0SEC filing ↗
2026-06-11Davidson MattAward / grant (A)Series A Preferred Stock1,923USD —USD —SEC filing ↗
2026-06-11Davidson MattAward / grant (A)Common Stock65,074USD —USD —SEC filing ↗
2026-04-07Shah VinayAward / grant (A)Common Stock17,325USD 0.00USD 0SEC filing ↗
2026-04-07Schuyler KevinAward / grant (A)Common Stock9,185USD 0.00USD 0SEC filing ↗
2026-04-07Goodman TonyAward / grant (A)Common Stock26,510USD 0.00USD 0SEC filing ↗
2026-04-07Gilliland Robertson H.Award / grant (A)Common Stock9,185USD 0.00USD 0SEC filing ↗
2026-04-07Claiborne Cary JAward / grant (A)Common Stock37,985USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerADIL
CIK0001513525
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history44 transaction lines from 2020-03-03 to 2026-07-16
17 P purchase lines · 3 S sale lines · 24 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.